Headworks Bio, Inc. recently announced the signing of a contract with STX Europe in Turku, Finland, for the finalization and commissioning of the Oasis of the Seas Cruise Ship wastewater treatment system. The system uses innovative moving bed bioreactor (MBBR) and return activated sludge technologies.
Oasis of the Seas is the world's largest cruise ship, built by STX Europe for Royal Caribbean Intl. It will have capacity for 5,400 guests onboard in 2,700 staterooms with a crew contingent of 2,160 members. All black, grey, galley, food waste and laundry wastewater generated onboard will be treated to a higher quality than the Alaska State Discharge Standards, currently the most stringent in the world. The maiden voyage of this technologically groundbreaking ship is scheduled for December 2009 and all systems will be functional and ready for passengers prior to launch.
"When the original wastewater treatment system supplier for the Oasis of the Seas was no longer able to complete the system in August of this year, we were more than relieved to have the Headworks Bio team step in so quickly," said Sami Hautala, vice president of STX Europe. "The transition to their group was made virtually seamless by the professionalism of their managers and the expertise of their engineers and technicians. Additionally, their team suggested improvements on the original design, which removed any doubt as to its operating efficiently under the most challenging of conditions. We've been extremely impressed by their determination to not only accomplish certification of the system on time for the ship's maiden voyage, but to ensure that the system is the best possible design aboard any cruise liner in the world. On many levels, Oasis of the Seas is a world-class engineering feat, including the unique biological system for treating its wastewater."
Headworks Bio, Inc., also announced that following its recent acquisition of Hydroxyl Systems, Inc., it has signed an agreement with Infilco Degremont, Inc. (IDI). Originally a licensee of Hydroxyl, IDI will continue to pursue the IFAS/MBBR market under the terms of a new agreement with Headworks Bio, which grants IDI full access to the ActiveCell Biofilm Carriers.
Source: Headworks Bio, Inc.